PE20060679A1 - Cis-imidazolinas como inhibidoras de la interaccion de la proteina mdm2 y los polipeptidos similares al p53 - Google Patents
Cis-imidazolinas como inhibidoras de la interaccion de la proteina mdm2 y los polipeptidos similares al p53Info
- Publication number
- PE20060679A1 PE20060679A1 PE2005000539A PE2005000539A PE20060679A1 PE 20060679 A1 PE20060679 A1 PE 20060679A1 PE 2005000539 A PE2005000539 A PE 2005000539A PE 2005000539 A PE2005000539 A PE 2005000539A PE 20060679 A1 PE20060679 A1 PE 20060679A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- interaction
- alcoxy
- imidazolines
- cis
- Prior art date
Links
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 title abstract 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 title abstract 2
- 230000003993 interaction Effects 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- -1 PIPERIDINYL Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical class F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
REFERIDA A UN COMPUESTO DERIVADO DE IMIDAZOLINA DE FORMULA I, DONDE X1 ES ALCOXI INFERIOR Y ALCOXI INFERIOR SUSTITUIDO POR TRIFLUOROMETILO O FLUOR; X2 ES H, HALOGENO, ALQUILO INFERIOR, ENTRE OTROS; X3 ES H, ALCOXI INFERIOR, HALOGENO, ENTRE OTROS; X4 Y X5 SON ALQUILO INFERIOR Y PUEDEN ESTAR UNIDOS ENTRE SI PARA FORMAR UN CICLOALQUILO; X6 ES CIANO, -CH2-OH, ENTRE OTROS; Y1 E Y2 SON H, ALQUILO INFERIOR, ENTRE OTROS; R ES PIPERIDINILO SUSTITUIDO POR UN HETEROCICLO DE 5 O 6 ESLABONES, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: CLORHIDRATO DE LA [(4S,5R)-2-(4-TERT-BUTIL-2-ETOXI-FENIL)-4,5-BIS-(4-FLUOR-FENIL)-4,5-DIHIDRO-IMIDAZOL-1-IL]-[4-(2-METANOSULFONIL-ETIL)-PIPERAZIN-1-IL]-METANONA, CLORHIDRATO DE LA 4-[(4S,5R)-2-(4-TERT-BUTIL-2-ETOXI-FENIL)-4,5-BIS-(4-FLUOR-FENIL)-4,5-DIHIDRO-IMIDAZOL-1-CARBO-NIL]-PIPERAZIN-2-ONA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS INHIBEN LA INTERACCION DE LA PROTEINA MDM2 CON LOS POLIPEPTIDOS SIMILARES AL P53 Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS TAL COMO EL CANCER
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57227504P | 2004-05-18 | 2004-05-18 | |
| US61553404P | 2004-10-01 | 2004-10-01 | |
| US66877205P | 2005-04-06 | 2005-04-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060679A1 true PE20060679A1 (es) | 2006-08-11 |
Family
ID=35058746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000539A PE20060679A1 (es) | 2004-05-18 | 2005-05-16 | Cis-imidazolinas como inhibidoras de la interaccion de la proteina mdm2 y los polipeptidos similares al p53 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7964724B2 (es) |
| EP (1) | EP1753727B1 (es) |
| JP (1) | JP4814228B2 (es) |
| KR (3) | KR20080027969A (es) |
| CN (1) | CN1953965B (es) |
| AR (1) | AR049545A1 (es) |
| AT (1) | ATE414693T1 (es) |
| AU (1) | AU2005243465B2 (es) |
| BR (1) | BRPI0511328A (es) |
| CA (1) | CA2565189A1 (es) |
| DE (1) | DE602005011132D1 (es) |
| ES (1) | ES2314660T3 (es) |
| IL (1) | IL178884A (es) |
| MX (1) | MXPA06013246A (es) |
| MY (1) | MY143800A (es) |
| NO (1) | NO20065730L (es) |
| PE (1) | PE20060679A1 (es) |
| RU (1) | RU2006144811A (es) |
| TW (1) | TW200600501A (es) |
| WO (1) | WO2005110996A1 (es) |
| ZA (1) | ZA200609595B (es) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7893278B2 (en) * | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
| KR20100031783A (ko) * | 2005-03-16 | 2010-03-24 | 에프. 호프만-라 로슈 아게 | 시스-２，４，５-트리아릴-이미다졸린 및 항암 약제로서의 그의 용도 |
| KR20100129331A (ko) | 2005-12-01 | 2010-12-08 | 에프. 호프만-라 로슈 아게 | 항암제로서 사용하기 위한 ｐ53 및 ｍｄｍ2 단백질 간 상호작용의 저해제로서의 2,4,5-트리페닐 이미다졸린 유도체 |
| BRPI0710477A2 (pt) | 2006-01-18 | 2011-08-16 | Hoffmann La Roche | cis-4, 5- biarila - 2- imidazolinas heterocìclicas como inibidores da mdm2 |
| AU2007269836A1 (en) | 2006-06-30 | 2008-01-10 | Albany Molecular Research, Inc. | Substituted piperidines that increase P53 activity and the uses thereof |
| JP2010510974A (ja) * | 2006-11-27 | 2010-04-08 | ノバルティス アーゲー | 置換ジヒドロイミダゾールおよび腫瘍の処置におけるその使用 |
| BRPI0720546A2 (pt) | 2006-12-14 | 2015-06-23 | Daiichi Sankyo Co Ltd | Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto |
| AU2008210434C8 (en) | 2007-01-31 | 2014-03-27 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| KR20160061439A (ko) | 2007-03-28 | 2016-05-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
| US7625895B2 (en) * | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
| KR101203020B1 (ko) | 2007-10-09 | 2012-11-20 | 에프. 호프만-라 로슈 아게 | 카이랄 시스-이미다졸린 |
| JPWO2009151069A1 (ja) | 2008-06-12 | 2011-11-17 | 第一三共株式会社 | ４，７−ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体 |
| DE102008047128A1 (de) | 2008-09-15 | 2010-04-15 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Verwendung von cis-Imidazolinen, insbesondere Nutlinen, zur Behandlung von chemoresistenten Krebserkrankungen |
| PL2380892T3 (pl) | 2009-01-16 | 2014-08-29 | Daiichi Sankyo Co Ltd | Pochodna imidazotiazolowa mająca strukturę pierścienia proliny |
| BR112012008849A2 (pt) | 2009-10-14 | 2015-09-22 | Schering Corp | composto, composição farmacêutica, e, uso de um composto |
| PH12012500870A1 (en) | 2009-11-12 | 2012-11-26 | Univ Michigan Regents | Spiro-oxindole mdm2 antagonists |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| WO2011106650A2 (en) * | 2010-02-27 | 2011-09-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| DK2603600T3 (da) | 2010-08-13 | 2019-03-04 | Aileron Therapeutics Inc | Peptidomimetiske makrocyklusser |
| WO2012045018A1 (en) | 2010-09-30 | 2012-04-05 | St. Jude Children's Research Hospital | Aryl-substituted imidazoles |
| PE20140408A1 (es) | 2010-11-12 | 2014-04-10 | Univ Michigan | Derivados espiro-oxindol como antagonistas de mdm2 |
| CA2829188C (en) | 2011-03-10 | 2016-10-18 | Daiichi Sankyo Company, Limited | Dispiropyrrolidine derivatives |
| EP2707372B1 (en) | 2011-05-11 | 2016-12-21 | The Regents Of The University Of Michigan | Spiro-oxindole mdm2 antagonists |
| US9376425B2 (en) | 2011-09-27 | 2016-06-28 | Amgen, Inc. | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
| WO2013054153A1 (en) | 2011-10-11 | 2013-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nutlin compounds for use in he treatment of pulmonary hypertension |
| RU2639523C2 (ru) | 2011-10-18 | 2017-12-21 | Эйлерон Терапьютикс, Инк. | Пептидомиметические макроциклы и их применение |
| WO2013062923A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp. | MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
| JP5992054B2 (ja) | 2011-11-29 | 2016-09-14 | ノバルティス アーゲー | ピラゾロピロリジン化合物 |
| WO2013096150A1 (en) | 2011-12-21 | 2013-06-27 | Merck Sharp & Dohme Corp. | Substituted piperidines as hdm2 inhibitors |
| US8815926B2 (en) | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
| CA2864120A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| RU2642299C2 (ru) | 2012-02-15 | 2018-01-24 | Эйлерон Терапьютикс, Инк. | P53 пептидомиметические макроциклы |
| EP2855483B1 (en) | 2012-05-24 | 2017-10-25 | Novartis AG | Pyrrolopyrrolidinone compounds |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| US9604919B2 (en) | 2012-11-01 | 2017-03-28 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| WO2014100065A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| EP2948453B1 (en) | 2013-01-22 | 2017-08-02 | Novartis AG | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
| US9403827B2 (en) | 2013-01-22 | 2016-08-02 | Novartis Ag | Substituted purinone compounds |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| AU2014223547B2 (en) | 2013-02-28 | 2017-11-16 | Amgen Inc. | A benzoic acid derivative MDM2 inhibitor for the treatment of cancer |
| US9758495B2 (en) | 2013-03-14 | 2017-09-12 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
| WO2014165816A1 (en) | 2013-04-05 | 2014-10-09 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
| WO2014191894A1 (en) | 2013-05-27 | 2014-12-04 | Novartis Ag | Imidazopyrrolidinone derivatives and their use in the treatment of disease |
| US8975417B2 (en) | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
| US9624247B2 (en) | 2013-05-28 | 2017-04-18 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease |
| KR20160012197A (ko) | 2013-05-28 | 2016-02-02 | 노파르티스 아게 | 피라졸로-피롤리딘-4-온 유도체 및 질환의 치료에서의 그의 용도 |
| CN104208066B (zh) * | 2013-06-03 | 2016-06-15 | 中国科学院遗传与发育生物学研究所 | 哌嗪衍生物作为p53分子调节剂的用途 |
| JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| EP3071571A1 (en) | 2013-11-21 | 2016-09-28 | Novartis AG | Pyrrolopyrrolone derivatives and their use as bet inhibitors |
| SG11201702223UA (en) | 2014-09-24 | 2017-04-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
| JP2018503595A (ja) | 2014-09-24 | 2018-02-08 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ペプチド模倣大環状分子およびその製剤 |
| PT3247699T (pt) | 2015-01-22 | 2019-08-06 | Sanofi Aventis Deutschland | Processo para a produção de 2-[4-(ciclopropanocarbonil)fenil]-2-metil-propanonitrilo |
| US10253067B2 (en) | 2015-03-20 | 2019-04-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
| CN109311900A (zh) | 2016-04-06 | 2019-02-05 | 密执安大学评议会 | 用于配体依赖性靶蛋白质降解的单官能中间体 |
| CA3020275A1 (en) | 2016-04-06 | 2017-10-12 | The Regents Of The University Of Michigan | Mdm2 protein degraders |
| EP3458101B1 (en) | 2016-05-20 | 2020-12-30 | H. Hoffnabb-La Roche Ag | Protac antibody conjugates and methods of use |
| WO2019079677A1 (en) * | 2017-10-20 | 2019-04-25 | Corbus Pharmaceuticals, Inc. | METHODS AND COMPOSITIONS RELATING TO 5- (1,1-DIMETHYLHEPTYL) -ORRESORCINOL ULTRAPUR |
| WO2020076660A1 (en) | 2018-10-08 | 2020-04-16 | The Regents Of The University Of Michigan | Small molecule mdm2 protein degraders |
| CA3171258A1 (en) | 2020-03-19 | 2021-09-23 | Nan JI | Mdm2 degraders and uses thereof |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| US11548866B1 (en) | 2021-11-22 | 2023-01-10 | Ligature Therapeutics Pte. Ltd. | Therapeutic compounds and methods of use thereof |
| US11504381B1 (en) * | 2021-11-22 | 2022-11-22 | Ligature Therapeutics Pte. Ltd. | Therapeutic compounds and methods of use thereof |
| KR102868976B1 (ko) | 2021-12-10 | 2025-11-03 | (주)잇마플 | 생체이용율과 이미다졸 펩타이드가 증가된 수용성 닭가슴살 가수분해물 및 그 제조방법 |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
| CN116903457A (zh) * | 2023-07-18 | 2023-10-20 | 上海添泽生物医药有限公司 | 一种2-羟基-5-异丙基苯甲酸的合成方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02101065A (ja) | 1988-10-06 | 1990-04-12 | Tanabe Seiyaku Co Ltd | イミダゾリン誘導体及びその製法 |
| DE4203547A1 (de) * | 1992-02-07 | 1993-08-12 | Knoll Ag | Verfahren zur racemattrennung von verapamil |
| FR2756560A1 (fr) * | 1996-12-04 | 1998-06-05 | Adir | Nouveaux derives de l'imidazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB2351082A (en) | 1999-06-18 | 2000-12-20 | Lilly Forschung Gmbh | Synthesis of Cyclic Substituted Amidines |
| US6653501B2 (en) * | 2001-06-27 | 2003-11-25 | Napro Biotherapeutics, Inc. | Chiral resolution method for producing compounds useful in the synthesis of taxanes |
| CN100486969C (zh) * | 2001-12-18 | 2009-05-13 | 霍夫曼-拉罗奇有限公司 | 顺式-2,4,5-三苯基-咪唑啉及其在肿瘤治疗中的应用 |
| ATE397925T1 (de) * | 2001-12-18 | 2008-07-15 | Hoffmann La Roche | Cis-imidazoline als mdm2-hemmer |
-
2005
- 2005-05-10 DE DE602005011132T patent/DE602005011132D1/de not_active Expired - Lifetime
- 2005-05-10 EP EP05742255A patent/EP1753727B1/en not_active Expired - Lifetime
- 2005-05-10 AT AT05742255T patent/ATE414693T1/de active
- 2005-05-10 KR KR1020087005155A patent/KR20080027969A/ko not_active Ceased
- 2005-05-10 MX MXPA06013246A patent/MXPA06013246A/es active IP Right Grant
- 2005-05-10 CA CA002565189A patent/CA2565189A1/en not_active Abandoned
- 2005-05-10 RU RU2006144811/04A patent/RU2006144811A/ru not_active Application Discontinuation
- 2005-05-10 KR KR1020067024089A patent/KR100832277B1/ko not_active Expired - Fee Related
- 2005-05-10 WO PCT/EP2005/005046 patent/WO2005110996A1/en not_active Ceased
- 2005-05-10 BR BRPI0511328-8A patent/BRPI0511328A/pt not_active IP Right Cessation
- 2005-05-10 KR KR1020117006619A patent/KR20110033964A/ko not_active Abandoned
- 2005-05-10 AU AU2005243465A patent/AU2005243465B2/en not_active Ceased
- 2005-05-10 ES ES05742255T patent/ES2314660T3/es not_active Expired - Lifetime
- 2005-05-10 CN CN200580015663XA patent/CN1953965B/zh not_active Expired - Fee Related
- 2005-05-10 JP JP2007517027A patent/JP4814228B2/ja not_active Expired - Fee Related
- 2005-05-13 US US11/129,621 patent/US7964724B2/en not_active Expired - Fee Related
- 2005-05-16 TW TW094115741A patent/TW200600501A/zh unknown
- 2005-05-16 AR ARP050101998A patent/AR049545A1/es not_active Application Discontinuation
- 2005-05-16 PE PE2005000539A patent/PE20060679A1/es not_active Application Discontinuation
- 2005-05-16 MY MYPI20052212A patent/MY143800A/en unknown
-
2006
- 2006-10-26 IL IL178884A patent/IL178884A/en not_active IP Right Cessation
- 2006-11-17 ZA ZA200609595A patent/ZA200609595B/xx unknown
- 2006-12-12 NO NO20065730A patent/NO20065730L/no not_active Application Discontinuation
-
2009
- 2009-02-05 US US12/366,381 patent/US20090143364A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1753727A1 (en) | 2007-02-21 |
| WO2005110996A1 (en) | 2005-11-24 |
| CN1953965B (zh) | 2012-07-04 |
| RU2006144811A (ru) | 2008-06-27 |
| ES2314660T3 (es) | 2009-03-16 |
| CA2565189A1 (en) | 2005-11-24 |
| JP2007538022A (ja) | 2007-12-27 |
| BRPI0511328A (pt) | 2007-12-04 |
| US20050288287A1 (en) | 2005-12-29 |
| KR20080027969A (ko) | 2008-03-28 |
| IL178884A (en) | 2010-12-30 |
| MY143800A (en) | 2011-07-15 |
| KR20110033964A (ko) | 2011-04-01 |
| US20090143364A1 (en) | 2009-06-04 |
| MXPA06013246A (es) | 2007-02-08 |
| KR100832277B1 (ko) | 2008-05-26 |
| AU2005243465B2 (en) | 2011-08-25 |
| CN1953965A (zh) | 2007-04-25 |
| EP1753727B1 (en) | 2008-11-19 |
| ZA200609595B (en) | 2008-06-25 |
| US7964724B2 (en) | 2011-06-21 |
| AU2005243465A1 (en) | 2005-11-24 |
| NO20065730L (no) | 2007-01-19 |
| KR20070011516A (ko) | 2007-01-24 |
| AR049545A1 (es) | 2006-08-16 |
| DE602005011132D1 (de) | 2009-01-02 |
| ATE414693T1 (de) | 2008-12-15 |
| TW200600501A (en) | 2006-01-01 |
| JP4814228B2 (ja) | 2011-11-16 |
| IL178884A0 (en) | 2007-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060679A1 (es) | Cis-imidazolinas como inhibidoras de la interaccion de la proteina mdm2 y los polipeptidos similares al p53 | |
| PE20060777A1 (es) | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas | |
| PE20080997A1 (es) | Compuestos n-fenilmetil-5-oxo-prolina-2-amida como moduladores de receptores p2x7 | |
| PE20080059A1 (es) | Quinazolinas para la inhibicion de pdk1 | |
| PE20090279A1 (es) | Derivados de 3,3-espiroindolinona como agentes antagonistas de mdm2 | |
| PE20060361A1 (es) | Compuestos heterociclicos como inhibidores de la cinesina mitotica | |
| PE20090229A1 (es) | DIFENIL-DIHIDRO-IMIDAZOPIRIDINONAS COMO INHIBIDORES DE LA INTERACCION DE MDM2 CON EL PEPTIDO p-53 | |
| PE20050020A1 (es) | DERIVADOS 4-(2-OXO-2,3-DIHIDRO-1-H-IMIDAZO[4,5-b]PIRIDIN-1-IL)-N-(2-OXO-AZEPAN-3-IL)PIPERIDINIL-1-CARBOXAMIDA SUSTITUIDOS COMO ANTAGONISTAS DEL RECEPTOR CGRP | |
| PE20081316A1 (es) | COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA | |
| PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
| AR049696A1 (es) | Derivados de indol | |
| PE20030188A1 (es) | Compuesto de anillo fundido como inhibidores de polimerasa del virus de la hepatitis c | |
| PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| PE20091095A1 (es) | Moduladores de gamma secretasa | |
| PE20090441A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA | |
| PE20070093A1 (es) | Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c | |
| PE20020753A1 (es) | Heteroaromaticos fusionados como activadores de la glucoquinasa | |
| CL2007001090A1 (es) | Compuestos derivados de diazepano, antagonistas de los receptores ccr-2, ccr-5 y ccr-3; procedimiento de preparacion; composicion farmaceutica; compuesto intermediario; y uso del compuesto en el tratamiento de una enfermedad oclusiva de arterias perifericas, isquemia critica de extremidades, angina inestable, apoplejia, entre otras | |
| PE20060599A1 (es) | DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1 | |
| PE20020084A1 (es) | N-(glicilo sustituido)-2-ciano-pirrolidinas como inhibidores de la dipeptidilpeptidasa-iv | |
| PE20070790A1 (es) | Derivados de 2-aminopirimidina como moduladores de la actividad del receptor de histamina h-4 | |
| PE20121506A1 (es) | Compuestos triazolopiridinas como inhibidores de c-met | |
| PE20120834A1 (es) | Derivados de furopirimidindiona como moduladores de trpa1 | |
| PE20081850A1 (es) | Derivados ciclizados como inhibidores de la eg-5 | |
| PE20080404A1 (es) | Derivados bencil-amino-piperidina como inhibidores de cetp |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |